▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3286 by analyst upside · 2026-08-12
THC
Tenet Healthcare Corporation
Healthcare · Market Cap $21B · P/E 10.0x
ANALYST PRICE TARGET
+8.7%
implied upside to consensus target
Current Price $259.45
Consensus Target $282.0
Bull Target $309.0
Bear Target $260.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
13
Hold
3
Sell
0
52-Week Low $157.58
52-Week High $265.32
YTD Return +30.1%
FUNDAMENTALS
Market Cap $21B
P/E Ratio (TTM) 10.0x
Forward P/E 12.5x
EPS (TTM) $25.86
PEG Ratio 1.88
Dividend Yield N/A
Revenue (TTM) $21.8B
Profit Margin 10.3%
52-WEEK RANGE
52-Week Low $157.58
52-Week High $265.32
Current Price $259.45
Bear Target $260.0
Bull Target $309.0
● Now $259.45 ● Target $282.0
TRADING DATA
Avg Volume 1.4M
YTD Return +30.1%
Analyst Count 21
Consensus Buy
Upside to Target +8.7%
Last Updated 2026-08-12

ANALYST SUMMARY

Tenet Healthcare Corporation (THC) is currently trading at $259.45 with a Wall Street consensus price target of $282.0, implying potential upside of 8.7% over the next 12 months. 21 analysts currently cover THC, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $309.0, while the most cautious has a target of $260.0.

THC operates in the Healthcare sector with a market capitalisation of $21B. The stock is up 30.1% year-to-date and is currently trading near the upper end of its 52-week range of $157.58 – $265.32.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UTHR +26.7%
United Therapeutics Corporation
$22B · P/E 18.5x · Buy
GMAB +25.5%
Genmab A/S
$19B · P/E 24.3x · Buy
STE +10.4%
STERIS plc
$23B · P/E 29.2x · Buy
DGX +3.5%
Quest Diagnostics Incorporated
$26B · P/E 25.2x · Buy
JAZZ +13.4%
Jazz Pharmaceuticals plc
$16B · P/E 17.0x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for THC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-05-05 Building track record
Baird - Reiterated
Neutral → Neutral 2026-05-05 Building track record
Stephens & Co. - Reiterated
Overweight → Overweight 2026-05-04 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-01 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-05-01 62% win rate (8 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-01 Building track record
Keybanc - Reiterated
Overweight → Overweight 2026-05-01 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-03-12 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
72
out of 100
Coverage depth
24/30
Consensus clarity
26/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →